BridgeBio
formerly BridgeBio PharmaIPOWe exist to bring meaningful medicines to patients quickly & safely.
Public · San Francisco Bay Area, United States · Founded 2014 · $1.7B raised
- Headquarters
- San Francisco Bay Area, California
- Employees
- 201–500
- Founded
- 2014
- Business Model
- Other
- Website
- bridgebio.com
- Total Funding
- $1.7B
- Last Round
- $500.0M Growth EquityJan 2024
- Rounds
- 5
- Type
- Public
About
BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. It has a late-stage investigational pipeline including Acoramidis for ATTRv, BBP-418 for LGMD2I/R9, Encaleret for ADH1 and hypoparathyroidism, Infigratinib for achondroplasia and hypochondroplasia, and BBP-812 for Canavan Disease.
Summary
BridgeBio is a Biotech company based in San Francisco Bay Area, United States, founded in 2014. It has raised $1.7B in total across 5 rounds, most recently a $500.0M Growth Equity round in Jan 2024. Investors include Blue Owl Capital, KKR and Viking Global.
Tech & App Stack
10 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Jun 2025
Sign up to see all 8 rounds
Series C through Debt Financing — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/bridgebio"><img src="https://indexed.vc/api/badge/company/bridgebio" alt="BridgeBio on Indexed.vc" width="260" height="76" /></a>